[go: up one dir, main page]

NO20065320L - Imidazolderivater anvendt som tafiainhibitorer - Google Patents

Imidazolderivater anvendt som tafiainhibitorer

Info

Publication number
NO20065320L
NO20065320L NO20065320A NO20065320A NO20065320L NO 20065320 L NO20065320 L NO 20065320L NO 20065320 A NO20065320 A NO 20065320A NO 20065320 A NO20065320 A NO 20065320A NO 20065320 L NO20065320 L NO 20065320L
Authority
NO
Norway
Prior art keywords
inhibitors
suppository
imidazole derivatives
derivatives used
compounds
Prior art date
Application number
NO20065320A
Other languages
English (en)
Inventor
Andreas Lindenschmidt
Christopher Kallus
Holger Heitsch
Sven Grueneberg
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065320(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NO20065320L publication Critical patent/NO20065320L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Oppfinnelsen angår forbindelser av formel (I) som er inhibitorer av den aktiverte trombin-aktiverende fibrinolyseinhibitor. Forbindelsene med formel (I) er egnet for produserende medikamenter for prevensjon og behandling av sykdommer ledsaget av tromboser, embolismer, hyperkoagulitet eller fibrotiske endringer.
NO20065320A 2004-04-22 2006-11-20 Imidazolderivater anvendt som tafiainhibitorer NO20065320L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004020186A DE102004020186A1 (de) 2004-04-22 2004-04-22 Heterocyclylessigsäuren als Inhibitoren von TAFla
PCT/EP2005/003630 WO2005105781A1 (de) 2004-04-22 2005-04-07 Imidazol-derivate als tafia-inhibitoren

Publications (1)

Publication Number Publication Date
NO20065320L true NO20065320L (no) 2007-01-12

Family

ID=34964308

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065320A NO20065320L (no) 2004-04-22 2006-11-20 Imidazolderivater anvendt som tafiainhibitorer

Country Status (34)

Country Link
EP (2) EP1864979B1 (no)
JP (1) JP4939401B2 (no)
KR (1) KR101162047B1 (no)
CN (1) CN100572376C (no)
AR (1) AR053302A1 (no)
AT (2) ATE386737T1 (no)
AU (1) AU2005238144B2 (no)
BR (1) BRPI0510159A (no)
CA (1) CA2563401C (no)
CR (1) CR8650A (no)
CY (1) CY1108087T1 (no)
DE (2) DE102004020186A1 (no)
DK (1) DK1740569T3 (no)
EC (1) ECSP066941A (no)
ES (1) ES2299026T3 (no)
HR (1) HRP20080099T3 (no)
IL (1) IL178672A (no)
MA (1) MA28543B1 (no)
MY (1) MY140903A (no)
NI (1) NI200600217A (no)
NO (1) NO20065320L (no)
NZ (1) NZ550757A (no)
PE (1) PE20060172A1 (no)
PL (1) PL1740569T3 (no)
PT (1) PT1740569E (no)
RS (1) RS50553B (no)
RU (1) RU2375356C2 (no)
SI (1) SI1740569T1 (no)
TN (1) TNSN06341A1 (no)
TW (1) TWI359016B (no)
UA (1) UA87306C2 (no)
UY (1) UY28868A1 (no)
WO (1) WO2005105781A1 (no)
ZA (1) ZA200607668B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2671861C (en) * 2006-12-06 2015-12-29 Sanofi-Aventis Urea and sulfamide derivatives as tafia inhibitors
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
EP2142538B1 (en) * 2007-02-13 2011-10-26 Schering Corporation Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists
CN101754962B (zh) 2007-07-19 2013-12-25 赛马拜制药公司 作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、三唑和四唑衍生物
EP2262783A2 (en) * 2008-02-21 2010-12-22 Sanofi-Aventis Covalently binding imaging probes
MX2010012793A (es) * 2008-06-06 2010-12-14 Sanofi Aventis Derivados de urea macrociclicos y de sulfamida como inhibidores de tafia.
NZ592764A (en) 2008-10-29 2012-08-31 Taisho Pharmaceutical Co Ltd Compound having tafia inhibitory activity
MY157304A (en) * 2009-05-15 2016-05-31 Sanofi Sa Process for the preparation of a compound useful as an inhibator of tafia
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2497566T3 (es) 2009-10-01 2014-09-23 Cymabay Therapeutics, Inc. Sales de tetrazol-1-il-fenoximetil-tiazol-2-il-piperidinil-pirimidina sustituida
EP2548872B1 (en) 2010-03-18 2016-09-28 Daiichi Sankyo Company, Limited Cyclopropanecarboxylic acid derivative
LT2548871T (lt) 2010-03-18 2017-09-25 Daiichi Sankyo Company, Limited Cikloalkilpakeistieji imidazolo dariniai
KR20130130737A (ko) 2010-11-11 2013-12-02 사노피 ３­（６­아미노­피리딘­３일）­２­아크릴산 유도체의 제조방법
WO2013076178A1 (en) 2011-11-25 2013-05-30 Sanofi Crystalline salts of r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
WO2013076179A1 (en) 2011-11-25 2013-05-30 Sanofi Sodium salt of (r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
US9156815B2 (en) 2011-11-25 2015-10-13 Sanofi Salt of (R)-3-(6-amino-pyridin-3-yl)-2-(1-Cyclohexyl-1H-imidazol-4-yl) ethyl propionate
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
SG11201509144YA (en) * 2013-06-10 2015-12-30 Sanofi Sa MACROCYCLIC UREA DERIVATIVES AS INHIBITORS OF TAFI<sb>A</sb>, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
US20190117624A1 (en) 2016-03-29 2019-04-25 Daiichi Sankyo Company, Limited Therapeutic agent for inflammatory bowel diseases
CN109862896A (zh) 2016-08-03 2019-06-07 西玛贝医药公司 用于治疗炎症性胃肠疾病或胃肠病症的氧亚甲基芳基化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2356838A1 (en) * 1998-12-24 2000-07-06 Fujisawa Pharmaceutical Co., Ltd. Imidazole compounds and medicinal use thereof
WO2003013526A1 (en) 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
EP1467732A1 (en) 2002-01-22 2004-10-20 Pfizer Limited 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases

Also Published As

Publication number Publication date
JP4939401B2 (ja) 2012-05-23
RU2375356C2 (ru) 2009-12-10
PE20060172A1 (es) 2006-03-31
SI1740569T1 (sl) 2008-06-30
CN1950357A (zh) 2007-04-18
ES2299026T3 (es) 2008-05-16
UY28868A1 (es) 2005-11-30
KR20070007346A (ko) 2007-01-15
EP1864979A1 (de) 2007-12-12
TW200602325A (en) 2006-01-16
WO2005105781A1 (de) 2005-11-10
CA2563401A1 (en) 2005-11-10
ECSP066941A (es) 2006-12-20
BRPI0510159A (pt) 2007-10-02
HRP20080099T3 (en) 2008-03-31
NI200600217A (es) 2008-06-17
PL1740569T3 (pl) 2008-07-31
ATE386737T1 (de) 2008-03-15
CR8650A (es) 2007-12-04
CA2563401C (en) 2012-08-07
RS50553B (sr) 2010-05-07
TNSN06341A1 (en) 2008-02-22
HK1101823A1 (zh) 2007-10-26
KR101162047B1 (ko) 2012-07-04
JP2007533672A (ja) 2007-11-22
ZA200607668B (en) 2008-03-26
CY1108087T1 (el) 2014-02-12
NZ550757A (en) 2010-06-25
DE502005002927D1 (de) 2008-04-03
ATE523505T1 (de) 2011-09-15
TWI359016B (en) 2012-03-01
IL178672A (en) 2011-08-31
CN100572376C (zh) 2009-12-23
AU2005238144B2 (en) 2010-08-26
DE102004020186A1 (de) 2005-11-17
AU2005238144A1 (en) 2005-11-10
PT1740569E (pt) 2008-03-31
DK1740569T3 (da) 2008-06-02
AR053302A1 (es) 2007-05-02
RU2006141246A (ru) 2008-06-10
EP1740569B1 (de) 2008-02-20
MY140903A (en) 2010-01-29
MA28543B1 (fr) 2007-04-03
EP1740569A1 (de) 2007-01-10
IL178672A0 (en) 2007-02-11
UA87306C2 (en) 2009-07-10
EP1864979B1 (de) 2011-09-07

Similar Documents

Publication Publication Date Title
NO20065320L (no) Imidazolderivater anvendt som tafiainhibitorer
NO20063449L (no) Substituerte heterocykler og deres anvendelse
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20072461L (no) Fremstilling og anvendelse av bifenyl-4-yl-karbonylaminosyre derivater for behandling av fedme
NO20082090L (no) Pyridopyrimidinoninhibitorer av P13K alfa
NO20090202L (no) Prolylhydroksylaseinhibitorer
NO20062561L (no) Kinoliner nyttige for behandling av kardiovaskulaere sykdommer
NO20072963L (no) 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
NO20081454L (no) Met-kinaseinhibitorer
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
NO20090628L (no) Pyridizinon derivativater
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
NO20070933L (no) Indazoler anvendbare i behandling av kardiovaskulaere sykdommer
NO20082346L (no) Hydrazonderivater og anvendelser derav
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
CY1117379T1 (el) Παραγωγα ιμιδαζολιου ως αναστολεις toy tafi-a
EA200970349A1 (ru) Ингибиторы металлопротеазы гетероциклического происхождения
NO20085212L (no) Nye pyridinanaloger
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
NO20083065L (no) Nye N-sulfamoylpiperidinamider for profylakse eller behandling av overvekt og beslektede tilstander
NO20073170L (no) Kaspaseinhibitorer og anvendelse derav
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application